Hepatology Research

Article	Citations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	250
Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study	70
Deceased Donation Disparities in East Asia—A Tale of Two Systems	57
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	43
Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study	39
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	38
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	32
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	31
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	31
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	30
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	29
Efficacy and Safety of Direct Oral Anticoagulants in Budd–Chiari Syndrome After Percutaneous Recanalization	28
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	28
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	27
Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy	26
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	24
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	24
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	23
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	22
Letter to the Editor: “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disea	22
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	21
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	21
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	21
Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation	21
Acknowledgment	20

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma	19
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	19
Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption	18
Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype	18
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study	17
The change from NAFLD to MAFLD expands fatty liver information flow	17
Issue Information	16
Issue Information	16
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	16
Issue Information	16
	16
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	16
Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	15
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	15
	15
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	15
Issue Information	14
The Nara Declaration: A New Collaborative Flow for Chronic Liver Disease Between Primary Care Physicians and Gastroenterologists/Hepatologists	14
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	14
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis	14
Metabolic Effect on Serum Mac‐2 Binding Protein Glycan Isomer Level and Its Normal Range in the Health Checkup Examinee	14
Chronic liver disease questionnaire to manage patients with chronic liver diseases	14
	14
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	14
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	13
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	13
Autoimmune Hepatitis: Histopathological Diversity and Its Clinical Implications	13
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	13
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis	13
Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	13
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	13
Issue Information	13
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	13
Post‐COVID‐19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan	13
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	13
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	12
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	12
Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders	12
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study	12
Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease	12
The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafte	12
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	12
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	12
Quantitative evaluation of tumor signal heterogeneity on gadoxetic acid‐enhanced magnetic resonance imaging as a predictor of postoperative survival and antitumor immunity in hepatocellular carcinoma	11
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	11
HCV Elimination Strategies for Maximum Effectiveness, Tailored to National and Regional Circumstances	11
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	11
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	11
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients	11
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	11

	11
	11
Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD	10
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	10
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	10
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	10
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	10
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	10
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	10
Cost‐effectiveness of hepatitis E virus vaccination strategy	10
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report	10
Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma	10
	10
Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies	9
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	9
Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES	9
Endoscopic Variceal Therapy and Transitional Care in Pediatric Portal Hypertension: A Review With a Focus on Long‐Term Outcomes and Adherence	9
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	9
Comment on “Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection”	9
Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development	9
Applying Cachexia Criteria to Cirrhosis: Considerations for Appropriate Interpretation and Future Research	9
	9
	9
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	8
Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma	8
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	8
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	8
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan	8
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease	8
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	8
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	8
Comment on “Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liv	8
The role of the nervous system in liver diseases	8
Issue Information	8
Letter to the Editor: “Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis”	8
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	8
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	7
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	7
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	7
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	7
Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20‐Year Population‐Based Study	7
Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma	7
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	7
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	7
Letter to the Editor: Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders	7
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	7
Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis	7
Erratum	7
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	7
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	7
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	7
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	7
Tamoxifen‐Induced Liver Injury in Patients With Breast Cancer: Frequency, Risk Factors and Clinical Course	6
Issue Information	6
Advancing Gene Mutation Analysis Through Post‐Ablation Liver Tumor Biopsy Specimens	6
Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma	6
Oncogenic Signaling Activation and Potential Biomarkers in Congestive Hepatopathy Revealed by Proteomic Analysis	6
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	6
	6
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	6
Cachexia in Cirrhosis Is Characterized by Sex‐Specific Loss of Muscle Mass and Adipose Tissue	6
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	6
Response to the Letter “Steatotic Liver Disease and the ‘Point of No Return’ in the Development of Metabolic Disorders”	6
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	6
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	6
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	6
Lipolysis‐Stimulated Lipoprotein Receptor Gene Variants as a Cause of Progressive Familial Intrahepatic Cholestasis: A Case Report	6
Issue Information	6
A Pharmacovigilance Study of Immune Checkpoint Inhibitor‐Associated Cholangitis: Insights From the FDA Adverse Event Reporting System	6
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	6
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	6
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	6
SOX9 Is a Key Factor for the Postnatal Maturation of the Intrahepatic Bile Duct Network	6
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade	6
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	6
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	6
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	6
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	6
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	6

Correlations Between Serum Bile Acids and Ammonia Levels in Patients With Cirrhosis	6
Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma	5
	5
Caution Regarding Short‐Term Increases in Ammonia Levels Following Splenic Artery Embolization	5
Analysis of HBV Genome Integration in Patients With HBV‐Previously Infected NBNC‐HCC	5
Clinical benefits of partial splenic embolization for cancer patients	5
The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography	5
Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis	5
Comment on “Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis”	5
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	5
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	5
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	5
Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations	5
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	5
The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging‐Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicente	5
Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	5
Acknowledgment	5
Mac‐2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis	5
Letter to the Editor: “Lymphocyte‐Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis”	5
Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study	5
	5
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	5
Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy	4
	4
Issue Information	4
Cachexia is an independent predictor of mortality in patients with cirrhosis	4
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study	4
An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	4
High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma	4
Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers	4
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	4
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	4
Autoimmune Hepatitis Profiles After Liver Transplantation in Latin American Patients: A Cluster Analysis of Clinical Outcomes	4
	4
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study	4
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study	4
A classification model for resectability in hepatocellular carcinoma patients	4
Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma	4
Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease	4
Issue Information	4
Issue Information	4
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study	4
Issue Information	4
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy	4
Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD	4
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma	4
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical	4
	4
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	4
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	4
Issue Information	4
Characteristic Hepatic Atrophy in Abemaciclib‐Induced Liver Injury: A Comparative Review of Three Cases	4
Pathological significance of intranuclear structures in liver biopsy samples	4
Acknowledgment	4
Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy	4
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	4
Issue Information	4
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease	4